Bayer's Kidney-Drug Expansion Hinges on an FDA Decision as Missouri Litigation and Farm Woes Test the Stock
Published on 10/08/2026 at 14:20 | Editorial boerse-global.de
Bayer shares slipped 1.6% to EUR 43.20 in Monday trading, a modest retreat that masks a far more consequential set of developments now converging on the Leverkusen-based group. The US Food and Drug Administration has accepted a supplemental application for Kerendia, Bayer's kidney-disease therapy, opening the door to a potentially sweeping expansion of the drug's addressable patient population. The agency's acceptance is procedural and explicitly does not constitute an approval, but it nonetheless represents a strategic milestone for the company's pharmaceutical division.
The commercial stakes are considerable. Roughly 850 million people worldwide live with chronic kidney disease, according to company figures, and more than half of them do not have diabetes. Kerendia's current authorization, granted in over 100 countries, is confined to patients with type 2 diabetes. Extending the label to the broader non-diabetic cohort would fundamentally widen the therapy's reach — a lever that matters more to the investment case than any single quarter's sales print.
Kerendia is already one of the faster-moving contributors to Bayer's pharma unit, generating EUR 603 million in revenue during the first half of 2026 under its existing indications. Should regulators sign off on the wider use, the drug could capture additional share in the cardiorenal segment.
Clinical Data Underpin the Filing
The confidence behind the application rests on results from the Phase III FIND-CKD trial, which enrolled 1,584 adults. Finerenone slowed the annual decline in kidney filtration rate by 0.7 units compared with placebo — a statistically significant margin. The therapy also cut the relative risk of combined renal and cardiovascular events by 23%. Those findings give regulators a scientific basis to consider the broader clearance.
Should investors sell immediately? Or is it worth buying Bayer?
Backing the therapeutic push is a substantial manufacturing build-out in North America. Bayer plans a pharmaceutical production site in New Albany, Ohio, carrying an investment of USD 2.2 billion. Construction is expected to begin in 2027, with production slated to start in 2031. The project is set to create roughly 600 jobs.
A Safety Signal That Warrants Attention
Not everything in the data package is straightforward. Elevated blood potassium occurred in 17% of treated patients versus 13.3% on placebo, a gap that could complicate day-to-day prescribing and necessitate close monitoring. Serious adverse events appeared at comparable rates across both arms. Regulators may also issue unexpected requests, impose delays, or reject the filing outright. And the Ohio plant will absorb significant capital for years before generating any return.
Wall Street Tempers Its Near-Term Enthusiasm
The pharma momentum is colliding with a softer read on Bayer's agricultural business. On October 1, JPMorgan analyst Richard Vosser trimmed short-term expectations for the third quarter while keeping an Overweight rating and a EUR 61 price target. Vosser cautioned that consensus estimates looked stretched, pointing to timing effects weighing on the crop-science unit. The note triggered visible selling; the stock closed at EUR 43.89 in the prior session.
The central question for investors is whether those agricultural headwinds reflect mere quarterly phasing or something more structural. Vosser's view is that the timing shifts barely alter full-year estimates — meaning the core business would remain on track and the issue would amount to little more than revenue moving between reporting periods. Should the coming numbers instead reveal sustained margin pressure in seeds and crop protection, the market would have to revisit its annual targets. The operating result of the Crop Science division will determine whether Bayer can shore up investor confidence.
Missouri Courtroom Reopens the Glyphosate Front
Legal uncertainty in the United States is far from resolved. On September 29, a trial began in Missouri involving damages claims brought by three women against Monsanto, Bayer's subsidiary. According to Reuters, the case serves as a legal test following the US Supreme Court's landmark ruling, and centers on allegations of defective product design and inadequate product safety in Roundup weedkillers. A plaintiff victory would signal a continuation of costly glyphosate litigation.
That exposure sits alongside a capital structure that limits financial flexibility. Bayer placed EUR 2 billion in hybrid bonds roughly two weeks ago, a move that secured liquidity but also underscored an ongoing refinancing need. If the agricultural unit underperformed in the third quarter, it could meaningfully erode group earnings — a scenario in which even encouraging pharma research progress would struggle to move the needle.
Bayer at a turning point? This analysis reveals what investors need to know now.
Pipeline Wins and a New Medical Chief
On the positive side of the ledger, Bayer strengthened its leadership on October 1, naming Dr. Christoph Koenen as Chief Medical Officer. Koenen now oversees the division's medical and scientific strategy in addition to his existing responsibilities. The development pipeline has also logged regulatory wins: the FDA granted Priority Review status to Lynkuet for vasomotor symptoms in hormone-receptor-positive breast cancer, while subsidiary BlueRock Therapeutics received Orphan Drug designation from both the FDA and the European Medicines Agency for its cell-therapy candidate lemiretprocel. Converting these advances into future revenue would give the shares room to run. At current levels, the stock sits well below its 52-week high of EUR 53.86.
The 200-Day Line and the November 3 Verdict
Technically, the picture narrows to a single threshold. So long as the shares hold above the 200-day moving average — cited at EUR 43.22 and EUR 43.19 in the two most recent reads — the broader uptrend for the year stays intact. A sustained break below that support would open the door to further downside and cloud the recovery signal.
The next hard catalyst is already circled: Bayer publishes its official third-quarter 2026 report on November 3. That release will show how heavily the agricultural timing effects actually weighed, and whether the full-year guidance holds. Until then, signals from the Missouri courtroom and expectations for the quarterly figures are likely to set the direction for the stock.
Ad
Bayer Stock: New Analysis - 8 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
